Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
Liz MorrellSarah WordsworthHowell FuSian ReesRichard BarkerPublished in: BMC health services research (2017)
The Scottish Medicines Consortium's reforms have allowed funding of up to 38 cancer drugs that might previously have been rejected. However, the contribution of specific elements of the reforms to the final decision is unclear. The process could be improved by increased transparency in how the non-quantitative inputs influence decisions. Some disparities in funding decisions between England and Scotland are likely to remain despite recent process convergence.